Loading resource…

Hiddo J.L. Heerspink, Ph.D., Andreas L. Birkenfeld, M.D., David Z.I. Cherney, M.D., Ph.D., Helen M. Colhoun, M.D., Per-Henrik Groop, M.D., Linong Ji, M.D., Niels Jongs, Ph.D., Chantal Mathieu, M.D., Richard E. Pratley, M.D., Sylvia E. Rosas, M.D.,
The research presents findings from a phase 3 trial that involved adults with type 1 diabetes and CKD, assessing the impact of finerenone on kidney and cardiovascular outcomes. The study compares the effects of finerenone against a placebo in participants receiving standard treatments for CKD. Results indicate significant changes in urinary albumin-to-creatinine ratios and safety profiles between the two groups, highlighting the potential benefits and risks associated with finerenone use in this population.
No account needed